Clik here to view.
Avistone Announces Updates on ANS014004
BEIJING Beijing Avistone Biotechnology Co., Ltd (also referred to as “Avistone Biotechnology” or “Avistone”), an innovative biotechnology company focused on precision oncology therapeutics, today...
View ArticleClik here to view.
Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab...
GALASHIELS & MARLOW, England Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim findings from...
View ArticleClik here to view.
Lifebit and Flatiron Health Bring Cutting-Edge Research Technology to Japan,...
TOKYO Flatiron Health, and Lifebit Biotech Ltd (UK, London; hereafter “Lifebit”), are expanding their collaboration into Japan to transform cancer care, facilitating ground breaking research by...
View ArticleClik here to view.
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for...
BENGALURU, India & HYDERABAD, India Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and...
View ArticleClik here to view.
欧盟公告机构（BSI荷兰）和欧洲药品管理局批准LeukoStrat® CDx FLT3突变检测在欧盟和欧洲经济区用于VANFLYTA®治疗
圣迭戈 (美国商业资讯)– Invivoscribe欣然宣布，其经过CE-2797 IVD认证的LeukoStrat® CDx FLT3突变检测已获得BSI（荷兰）和欧洲药品管理局(EMA)批准，可用于辅助选择欧盟和欧洲经济区新诊断的FLT3-ITD阳性急性髓系白血病(AML)个体患者，这些患者可能有资格接受Daiichi...
View ArticleClik here to view.
EUの認証機関であるBSIオランダおよびEMAがLeukoStrat ® CDx FLT3 Mutation...
サンディエゴ （ビジネスワイヤ） — インビボスクライブは、CE-2797 IVD認証を取得したLeukoStrat® CDx FLT3 Mutation...
View ArticleClik here to view.
Avania收购西班牙医疗技术临床研究机构（CRO）Anagram， 以加强其在欧洲新兴地区的核心CRO服务
荷兰比尔特霍芬 (美国商业资讯)– 全球首屈一指的医疗技术受托研究机构（CRO）和咨询服务合作伙伴Avania今天宣布收购Anagram。Anagram总部位于西班牙巴塞罗那，是伊比利亚半岛领先的医疗技术CRO之一，为西班牙以及更广泛的欧洲市场与其他地区的客户提供医疗技术解决方案。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Clik here to view.
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a Phase 1 study of ZL-1310, the Company’s investigational antibody-drug conjugate...
View ArticleClik here to view.
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study...
View ArticleClik here to view.
Inocras Unveils Breakthrough Study, Proving Target-Enhanced Whole-Genome...
SAN DIEGO Inocras, an industry leader in whole genome sequencing and bioinformatics, released a new study highlighting the clinical validation of its CancerVision Target-Enhanced Whole-Genome...
View ArticleClik here to view.
MEDiC Life Sciences Announces Collaboration with Hanmi Pharmaceutical on...
MOUNTAIN VIEW, Calif. MEDiC Life Sciences (“MEDiC”), a Silicon Valley biotech startup, today announced that it has entered a research collaboration with Hanmi Pharmaceutical (“Hanmi”), a leading...
View ArticleClik here to view.
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2024 and recent corporate updates, before...
View ArticleClik here to view.
Sunbird Bio Raises Additional $14 Million to Advance Broadest Blood-Based...
CAMBRIDGE, Mass. and SINGAPORE Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage...
View ArticleClik here to view.
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the...
View ArticleClik here to view.
Zai Lab Announces Participation in November and December Investor Conferences
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences...
View ArticleClik here to view.
ノボキュアのOptune Lua®、転移性非小細胞肺がんの治療用としてFDAの承認を取得
スイス、ロート （ビジネスワイヤ） — ノボキュア（NASDAQ：NVCR）は、プラチナ製剤ベースのレジメンによる治療中または治療後に疾患進行が認められた転移性非小細胞肺がん（mNSCLC）の成人患者の治療において、Optune Lua®のPD-1／PD-L1阻害剤またはドセタキセル治療との併用療法がアメリカ食品医薬品局（FDA）によって承認されたと発表しました。...
View ArticleClik here to view.
藤田医科大学羽田クリニックにおいてBostonGene 社が開発したTumor Portrait™検査を導入。がん患者さんの包括的ゲノム検査として開始します。
東京 & WALTHAM, Mass. （ビジネスワイヤ） — AIによる分子免疫プロファイリングソリューションのリーディングカンパニーであるBostonGeneは、藤田医科大学羽田クリニックにてBostonGene社開発の Tumor Portrait™を用いたがんゲノムプロファイリング検査を開始します。...
View ArticleClik here to view.
Fujita Health University and BostonGene Expand Access to Genomic Cancer...
TOKYO & WALTHAM, Mass. Fujita Health University and BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that the Fujita Health University Haneda...
View ArticleClik here to view.
LigaChem Biosciences Appoints Rodrigo Ruiz Soto as Chief Medical Officer
DAEJEON, South Korea LigaChem Biosciences, Inc. (KOSDAQ: 141080), a leader in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced the appointment of...
View Article